Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer).

Several clinical trials have demonstrated the benefit of adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The comparison of outcomes between nonrandomized groups of patients who received similar treatments in routine practice remains difficult. The present study aimed to evaluate the pathological complete response (pCR) rates achieved with pertuzumab among patients in routine clinical care in Peru using real-world data.

Working toward a common goal: a collaborative obstetrics and gynecology practice.

Health care reform in the United States will continue to necessitate creativity in the organization and staffing of health care models. The Department of Obstetrics and Gynecology at Bronx-Lebanon Hospital Center has expanded its staff by placing midwives as primary providers for most routine care and much of the specialty care offered within the department. Midwives and attending physicians work collaboratively in outpatient specialty clinics.